Unnamed: 0,pubmed_id,Title,CreatedDate,Abstract
0,34281299,Management of large perforations of the sinus mucosa with PRGF-Endoret(R) platelet concentrate.,['2021/07/20 04:48'],aim present study describe new technique possible complete maxillary sinus lift procedure even case severe damage complete removal sinus mucosa using prgfendoretr platelet concentrate eighteen patients ratio fm45 average age 582 years ds 885 years severe perforation 10 millimetres diameter sinus mucosa maxillary sinus lift procedure selected normally procedure interrupted due impossible stabilization graft material inside subantral cavity contrary protocol foreseen sealing perforation using prgf autologous gel membranes creation new sinus pseudomembrane graft material covered prgfendoret obtained according protocol developed bti biotechnology institute vitoria spain 14 cases 18 implant fixtures concurrently inserted 4 cases fixture insertion postponed 6 months 37 fixtures inserted 27 time 10 6 months 2 months surgery cbct showed correct pneumatization maxillary sinus 16 patients 18 89 cases 12 months radiological normalization maxillary sinus present 17 patients 18 bringing healing rate 94 cases regarding implant healing 2 37 implants inserted lost first month surgical phase whereas 12 months prosthesis application 35 implants perfectly osteointegrated healing rate equal 946 fixtures 36 months surgery fixtures osteointegrated 35 37 implants percentage 946 success may conclude use prgf allowed complete sinus lift even case severe perforation sinus mucosa total removal thanks capability stabilize graft antibacterial antifungal activity anabolic effect favouring bone regeneration
1,34143970,"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.",['2021/06/18 20:10'],background patients ovarian cancer relapse receiving frontline platinumbased chemotherapy eventually develop platinumresistant platinumrefractory disease report results avelumab alone avelumab plus pegylated liposomal doxorubicin pld compared pld alone patients platinumresistant platinumrefractory ovarian cancer methods javelin ovarian 200 openlabel parallelgroup threearm randomised phase 3 trial done 149 hospitals cancer treatment centres 24 countries eligible patients aged 18 years older epithelial ovarian fallopian tube peritoneal cancer maximum three previous lines platinumsensitive disease none platinumresistant disease eastern cooperative oncology group performance status 0 1 patients randomly assigned 111 via interactive response technology avelumab 10 mgkg intravenously every 2 weeks avelumab plus pld 40 mgm2 intravenously every 4 weeks pld stratified disease platinum status number previous anticancer regimens bulky disease primary endpoints progressionfree survival blinded independent central review overall survival randomly assigned patients objective show whether avelumab alone avelumab plus pld superior pld safety assessed patients received least one dose study treatment trial registered clinicaltrialsgov nct02580058 trial longer enrolling patients final analysis primary endpoints findings jan 5 2016 may 16 2017 566 patients enrolled randomly assigned combination n188 pld n190 avelumab n188 data cutoff sept 19 2018 median duration followup overall survival 184 months iqr 156219 combination group 174 months 152213 pld group 182 months 158212 avelumab group median progressionfree survival blinded independent central review 37 months 95 ci 3351 combination group 35 months 2140 pld group 19 months 1819 avelumab group combination vs pld stratified hr 078 repeated 931 ci 059124 onesided p0030 avelumab vs pld 168 132260 onesided p099 median overall survival 157 months 95 ci 127187 combination group 131 months 118155 pld group 118 months 89141 avelumab group combination vs pld stratified hr 089 repeated 8885 ci 074124 onesided p021 avelumab vs pld 114 095158 onesided p083 common grade 3 worse treatmentrelated adverse events palmarplantar erythrodysesthesia syndrome 18 10 combination group vs nine 5 pld group vs none avelumab group rash 11 6 vs three 2 vs none fatigue ten 5 vs three 2 vs none stomatitis ten 5 vs five 3 vs none anaemia six 3 vs nine 5 vs three 2 neutropenia nine 5 vs nine 5 vs none neutrophil count decreased eight 5 vs seven 4 vs none serious treatmentrelated adverse events occurred 32 18 patients combination group 19 11 pld group 14 7 avelumab group treatmentrelated adverse events resulted death one patient pld group sepsis avelumab group intestinal obstruction interpretation neither avelumab plus pld avelumab alone significantly improved progressionfree survival overall survival versus pld results provide insights patient selection future studies immune checkpoint inhibitors platinumresistant platinumrefractory ovarian cancer funding pfizer merck kgaa darmstadt germany
2,34122682,"The Effect of Combined Vitamin C and Vitamin E Supplementation on Oxidative Stress Markers in Women with Endometriosis: A Randomized, Triple-Blind Placebo-Controlled Clinical Trial.",['2021/06/14 09:39'],background endometriosis chronic estrogendependent pelvic inflammatory disease may various causes oxidative stress dysmenorrhea dyspareunia pelvic pain wellknown symptoms endometriosis present clinical trial assessed role supplementation antioxidant vitamins indices oxidative stress well severity pain women endometriosis materials methods enrolled 60 reproductiveaged 1545 years women pelvic pain tripleblind clinical trial 13 stages laparoscopicproven endometriosis participants randomized group n 30 given vitamin c 1000 mgday 2 tablets 500 mg vitamin e 800 iuday 2 tablets 400 iu combination group b n 30 given placebo pills daily 8 weeks results following treatment vitamin c vitamin e found significant reduction mda ros compared placebo group significant decline total antioxidant capacity treatment however severity pelvic pain p value 0001 dysmenorrhea p value 0001 dyspareunia p value 0001 significantly decreased treatment group 8 weeks supplementation conclusions present findings support potential role antioxidants management endometriosis intake vitamin c vitamin e supplements effectively reduced dysmenorrhea severity improved dyspareunia severity pelvic pain
3,34082142,"Effect of fresh pomegranate juice on the pharmacokinetic profile of artemether: An open-label, randomized, 2- period crossover study in healthy human volunteers.",['2021/06/03 20:17'],study designed evaluate effect fresh pomegranate punica granatum l juice pharmacokinetic profile artemether healthy volunteers randomized openlabel crossover study conducted healthy subjects n 26 volunteer received 250 ml fresh pomegranate juice twice daily 2 weeks day 14 administered single oral dose artemether 80 mg either water 250 ml pomegranate juice thirteen blood samples collected 12 h 6 electrocardiograms recorded plasma concentrations artemether metabolite dihydroartemisinin analyzed noncompartmental method using lcmsms lower limit detection llod lower limit quantification lloq artemether estimated 03 08 ngml respectively dihydroartemisinin 02 06 ngml respectively pharmacokinetic parameters artemether dihydroartemisinin significantly altered coadministered fresh pomegranate juice auc 0infinity slightly increased 742 859 ngml artemether geometric mean ratio 114 95 ci 108118 p 045 699 818 ngml dihydroartemisinin geometric mean ratio 115 95 ci 109 115 p 04 difference cmax artemether also statistically nonsignificant 173 vs 195 ngml geometric mean ratio 109 95 ci 091 115 p 061 likewise elimination halflife t12 artemether dihydroartemisinin remained unchanged p 043 031 respectively addition significant difference tmax artemether p 066 metabolite p 065 conclusion findings present study demonstrated administration pomegranate juice significant effect pharmacokinetic profile artemether
4,34081625,The effects of psyllium husk on gut microbiota composition and function in chronically constipated women of reproductive age using 16S rRNA gene sequencing analysis.,['2021/06/03 17:16'],chronic constipation common gastrointestinal disorder occurs elderly women psyllium husk widely used treat condition recent studies shown psyllium husk improve clinical symptoms constipation regulating gut microbiota clinical effects potential mechanisms constipated women reproductive age previously investigated compared fecal microbiota treatment placebo n 29 psyllium husk n 25 using 16s ribosomal ribonucleic acid rrna gene sequencing analysis psyllium husk relieved symptoms constipated women reproductive age sequencing results showed psyllium husk group exhibited different gut microbiota composition compared placebo group moreover network analysis indicated significant correlations clustering operational taxonomic units otus psyllium husk group kyoto encyclopedia genes genomes kegg annotation analysis showed relative abundances metabolismrelated kegg pathways enriched psyllium husk group conclusion findings suggest composition gut microbiota altered symptoms constipation alleviated via psyllium husk intervention changes metabolic function might related constipation furthermore studies warranted elucidate potential metabolic mechanisms contributing chronic constipation
5,34079535,Innate Lymphoid Cells Activation and Transcriptomic Changes in Response to Human Dengue Infection.,['2021/06/03 06:40'],background dengue virus denv infection global impact public health clinical outcomes denv vary flulike illness called dengue fever df severe form known dengue hemorrhagic fever dhf underlying innate immune mechanisms leading protective detrimental outcomes fully elucidated helper innate lymphoid cells hilcs innate lymphocyte recently discovered functionally resemble thelper cells important inflammation homeostasis however role hilcs denv infection unexplored methods performed flow cytometry investigate frequency phenotype hilcs peripheral blood mononuclear cells denvinfected patients different disease severities df dhf different phases febrile convalescence infection intracellular cytokine staining hilcs df dhf also evaluated flow cytometry ex vivo stimulation hilcs sorted subjected transcriptome analysis using rna sequencing differential gene expression analysis performed compare febrile convalescent phase samples df dhf selected differentially expressed genes validated quantitative pcr results phenotypic analysis showed marked activation three hilc subsets febrile phase shown higher cd69 expression compared paired convalescent samples although frequency hilcs remained unchanged upon ex vivo stimulation hilcs febrile phase dhf produced significantly higher ifngamma il4 compared df transcriptomic analysis showed unique hilcs gene expression df dhf suggesting divergent functions hilcs may associated different disease severities differential gene expression analysis indicated hilcs function cytokine secretion cytotoxicity febrile phase denv infection conclusions helper ilcs activated febrile phase denv infection display unique transcriptomic changes well cytokine production correlate severity targeting hilcs early innate response denv might help shape subsequent immune responses potentially lessen disease severity future
6,34078408,Planned early delivery for late preterm pre-eclampsia in a low- and middle-income setting: a feasibility study.,['2021/06/03 05:42'],background preeclampsia leading cause maternal perinatal mortality morbidity globally planned delivery 340 366 weeks may reduce adverse pregnancy outcomes yet evaluated low middleincome setting prior designing randomised controlled trial evaluate india zambia carried 6month feasibility study order better understand proposed trial environment guide development intervention methods used mixed methods understand disease burden current management preeclampsia proposed trial sites explore acceptability intervention undertook case notes review women preeclampsia delivered proposed trial sites 3month period alongside facilitating focus group discussions women partners conducting semistructured interviews healthcare providers descriptive statistics used analyse audit data thematic framework analysis used qualitative data results case notes data n 326 showed settings 195 n 44 women preeclampsia delivering beyond 34 weeks experienced adverse outcome women delivering 340 366 weeks similar numbers antenatal stillbirths n 3 33 neonatal deaths n 3 34 median infant birthweight 22 kg 19 kg zambia india respectively lived experience women healthcare providers important facilitator proposed intervention highlighting serious consequences preeclampsia preference spontaneous labour limited neonatal resources identified potential barriers conclusions study demonstrated clear need evaluate intervention highlighted several challenges relating trial context enabled us adapt protocol design acceptable intervention study demonstrates importance assessing feasibility developing complex interventions particularly lowresource setting additionally provides unique insight management preeclampsia trial settings understanding knowledge attitudes beliefs underpinning acceptability planned early delivery
7,34069412,COVID-19 Disease Severity and Death in Relation to Vitamin D Status among SARS-CoV-2-Positive UAE Residents.,['2021/06/02 01:25'],insufficient blood levels neurohormone vitamin associated increased risk covid19 severity mortality despite global rollout vaccinations promising preliminary results focus remains additional preventive measures manage covid19 results conflict vitamin ds plausible role preventing treating covid19 examined relation vitamin status covid19 severity mortality among multiethnic population united arab emirates observational study used data 522 participants tested positive sarscov2 one main hospitals abu dhabi dubai 464 patients included data analysis demographic clinical data retrospectively analyzed serum samples immediately drawn first hospital visit used measure serum 25hydroxyvitamin 25ohd concentrations automated electrochemiluminescence levels 12 ngml significantly associated higher risk severe covid19 infection death age independent risk factor whereas comorbidities smoking contribute outcomes upon adjustment sex patients important predictor severity death study first conducted uae measure 25ohd levels sarscov2positive patients confirm association levels 12 ngml covid19 severity mortality
8,34037760,"Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial.",['2021/05/26 12:34'],objectives severe acute respiratory syndrome coronavirus 2 sarscov2 responsible covid19 pandemic majority patients experience asymptomatic mild selflimited disease cases progress respiratory multiorgan failure however far approved antiviral therapy available treatment covid19 sofosbuvirvelpatasvir sofvel approved antihcv drug capable suppressing families positivesense rna viruses conserved polymerase may effective sarscov2 study conducted evaluate efficacy sofvel combination addition national standard care versus national standard care alone hydroxychloroquine lopinavirritonavir well supportive care patients moderate severe covid19 infection methods singlecentre randomized openlabelled prospective clinical trial done patients moderate severe covid19 admitted farabi hospital kermanshah province iran eligible patients randomly assigned 11 ratio sofvel arm sofvel plus national standard care control arm national standard care alone main outcome study mortality day 28 randomization secondary outcomes time start medication clinical improvement hospital length stay need mechanical ventilation duration mechanical ventilation conversion rtpcr results positive negative time randomization discharge adverse events evaluated patients started assigned treatment results 11 april 8 june 2020 80 patients recruited randomly assigned sofvel n 40 control n 40 arms primary outcome significantly different two arms p 100 secondary outcomes including time clinical improvement hospital length stay need mechanical ventilation duration mechanical ventilation rtpcr conversion significantly different arms either p 005 sofvel treatment national standard care tolerated similarly conclusions although treatment sofvel safe adding sofvel standard care improve clinical status reduce mortality patients moderate severe covid19 however larger randomized clinical trials including parameters needed accurate estimation efficacy sofvel
9,34019819,"Chemotherapy de-escalation using an (18)F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.",['2021/05/21 20:13'],background several deescalation approaches investigation patients her2positive earlystage breast cancer assessed early metabolic responses neoadjuvant trastuzumab pertuzumab using 18ffluorodeoxyglucose 18ffdgpet 18ffdgpet possibility chemotherapy deescalation using pathological responseadapted strategy methods multicentre randomised openlabel noncomparative phase 2 trial 45 hospitals spain france belgium germany uk italy portugal eligible participants women aged 18 years older centrally confirmed her2positive stage iiiia invasive operable breast cancer 15 cm tumour size least one breast lesion evaluable 18ffdgpet eastern cooperative oncology group performance status 0 1 baseline left ventricular ejection fraction least 55 randomly assigned participants 14 via interactive response system using central block randomisation block sizes five stratified hormone receptor status either docetaxel 75 mgm2 intravenous carboplatin area concentrationtime curve 6 mgml per min intravenous trastuzumab subcutaneous 600 mg fixed dose pertuzumab intravenous 840 mg loading dose 420 mg maintenance doses group trastuzumab pertuzumab group b hormone receptorpositive patients allocated group b additionally given letrozole postmenopausal 25 mgday orally tamoxifen premenopausal 20 mgday orally centrally reviewed 18ffdgpet scans done randomisation two treatment cycles patients assigned group completed six cycles treatment every 3 weeks regardless 18ffdgpet results patients assigned group b initially received two cycles trastuzumab pertuzumab 18ffdgpet responders group b continued treatment six cycles 18ffdgpet nonresponders group switched six cycles docetaxel carboplatin trastuzumab pertuzumab surgery done 26 weeks last dose study treatment adjuvant treatment selected according neoadjuvant treatment administered pathological response hormone receptor status clinical stage diagnosis coprimary endpoints proportion 18ffdgpet responders group b pathological complete response breast axilla ypt0is ypn0 determined local pathologist surgery eight cycles treatment 3year invasive diseasefree survival patients group b assessed intention treat definitive assessment pathological complete response done primary analysis followup assess invasive diseasefree survival continuing hence data included article safety assessed participants received least one dose study drug healthrelated qualityoflife assessed eortc qlqc30 qlqbr23 questionnaires baseline two cycles treatment surgery trial registered eudract 201600267627 clinicaltrialsgov nct03161353 ongoing findings june 26 2017 april 24 2019 randomly assigned 71 patients group 285 group b median followup 57 months iqr 5360 227 80 285 patients group b 18ffdgpet responders 86 379 95 ci 316445 p00001 compared historical rate 227 pathological complete response common haematological grade 34 adverse events anaemia six 9 68 patients group vs four 1 283 patients group b neutropenia 16 24 vs ten 4 febrile neutropenia 14 21 vs 11 4 serious adverse events occurred 20 29 68 patients group versus 13 5 283 patients group b deaths reported neoadjuvant treatment global health status declined least 10 650 95 ci 465724 355 297417 patients groups b respectively interpretation 18ffdgpet identified patients her2positive earlystage breast cancer likely benefit chemotherapyfree dual her2 blockade trastuzumab pertuzumab reduced impact global health status depending forthcoming results 3year invasive diseasefree survival endpoint strategy might valid approach select patients requiring chemotherapy funding f hoffmannla roche
10,33994796,A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies.,['2021/05/17 05:59'],background crizotinib inhibits alk met ros1 tyrosine kinases development resistance monotherapy issue antiangiogenic properties pazopanib could overcome crizotinib drug resistance additionally antiangiogenic properties crizotinib could augment clinical efficacy pazopanib methods evaluated safety responses patients advanced solid tumors treated crizotinib pazopanib results eightytwo patients median age 53 years range 1878 years enrolled median number prior systemic therapies 3 range 08 able dose escalate dose level 8 crizotinib 250 mg twice daily pazopanib 800 mg daily mtd identified grade 3 4 toxicities seen 32 patients highest prevalence fatigue n9 11 diarrhea n6 7 vomiting n3 4 anemia n2 2 alt increased n2 2 82 patients 61 74 measurable disease recistv11 reached first restaging 6 weeks partial response pr observed 661 10 patients stable disease sd lasting 6 months observed 1061 patients 16 total 1661 26 patients sd 6 monthspr conclusion dose level 6 crizotinib 200 mg twice daily pazopanib 600 mg daily tolerable dosing combination used future studies also observed moderate clinical activity patients advanced solid tumors received numerous prior therapies
11,33989558,"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.",['2021/05/14 20:09'],background patients relapsed refractory diffuse large bcell lymphoma dlbcl respond progressive disease salvage therapies poor prognosis loncastuximab tesirine cd19directed antibodydrug conjugate encouraging phase 1 singleagent antitumour activity acceptable safety nonhodgkin lymphoma aimed evaluate antitumour activity safety loncastuximab tesirine patients relapsed refractory dlbcl methods multicentre 28 hospital sites usa uk italy switzerland openlabel singlearm phase 2 trial lotis2 patients aged 18 years older relapsed refractory dlbcl two multiagent systemic treatments measurable disease eastern cooperative oncology group performance status 02 eligible patients received loncastuximab tesirine intravenously day 1 21day cycle 150 mugkg two cycles 75 mugkg thereafter 1 year disease relapse progression unacceptable toxicity death major protocol deviation pregnancy patient investigator sponsor decision primary endpoint overall response rate assessed central review primary antitumour activity safety analyses done astreated population patients received least one dose loncastuximab tesirine responding patients least 6 months followup initial documented response enrolment complete trial registered clinicaltrialsgov nct03589469 findings aug 1 2018 sept 24 2019 184 patients assessed eligibility 145 79 enrolled received least one dose loncastuximab tesirine including patients highrisk characteristics poor prognosis doublehit triplehit transformed primary refractory dlbcl 70 145 patients complete partial response overall response rate 483 95 ci 399567 35 complete response 35 partial response common grade 3 higher treatmentemergent adverse events neutropenia 37 26 145 patients thrombocytopenia 26 18 increased gammaglutamyltransferase 24 17 serious adverse events reported 57 39 145 patients treatmentemergent adverse events fatal outcome occurred eight 6 145 patients none considered related loncastuximab tesirine interpretation loncastuximab tesirine substantial singleagent antitumour activity produces durable responses acceptable safety profile potentially offering new therapeutic option heavily pretreated patients relapsed refractory dlbcl funding adc therapeutics
12,33947099,Assessment of Body Composition and Dietary Intake in Nursing-Home Residents: Could Lessons Learned from the COVID-19 Pandemic Be Used to Prevent Future Casualties in Older Individuals?,['2021/05/05 01:03'],population older adults especially living nursing homes growing sedentary lifestyle possible poor nutrition nursing homes place residents nhrs risk body composition impairments malnutrition subsequently numerous chronic diseases aim study assess body composition including body fluids dietary intake nhrs association osteosarcopenic adiposity syndrome osa components osteopenic adiposity oa sarcopenic adiposity sa adiposityonly ad specific macro micronutrients evaluated well study included 84 participants 821 women aged 653952 years body composition assessed advanced bioelectrical impedance device biaaccr dietary intake assessed via 24h recall analyzed using nutrition software majority 95 participants overweight high body fat low muscle bone mass leading high prevalence osa 50 oa 13 ad 26 participants sa analyzed highest extracellular watertotal body water ratio observed osa participants indicating heightened inflammatory state participants three body composition categories similar nutrient intake protein fiber omega3 fatty acids almost micronutrients far recommendations conclusion high prevalence osa among nhrs accompanied poor dietary intake could place residents high risk covid19 infections therefore optimization body composition nutritional status included along standard medical care order provide better health maintenance particularly covid19 era
13,33916192,"The Effectiveness of Probiotic Lactobacillus rhamnosus and Lactobacillus casei Strains in Children with Atopic Dermatitis and Cow's Milk Protein Allergy: A Multicenter, Randomized, Double Blind, Placebo Controlled Study.",['2021/04/30 01:02'],probiotics seem promising effects prevention treatment allergic conditions including atopic dermatitis ad food allergy purpose multicenter randomized placebocontrolled trial evaluate effectiveness probiotic preparation comprising lactobacillus rhamnosus lock 0900 lactobacillus rhamnosus lock 0908 lactobacillus casei lock 0918 children 2 years age ad cows milk protein cmp allergy study enrolled 151 children whoapart treated cmp elimination dietwere randomized receive probiotic preparation daily dose 109 bacteria placebo three months subsequent ninemonth followup primary outcomes included changes ad symptom severity assessed scoring ad scorad index proportion children symptom improvement scorad score decreased least 30 comparison baseline threemonth intervention probiotic placebo groups showed significant p 00001 decrease scorad scores maintained nine months later percentage children showed improvement significantly higher probiotic placebo group odds ratio 256 95 confidence interval ci 11358 p 0012 three months probiotics induced scorad improvement mainly allergen sensitized patients 603 95 ci 1851967 p 0001 positive effect observed nine months results showed mixture probiotic lock strains offers benefits children ad cmp allergy research necessary assess effect probiotic supplementation development immune tolerance nct04738565
14,33909203,Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and >/= 2 prior HER2-directed regimens.,['2021/04/28 12:27'],purpose characterize healthrelated quality life hrqol patients human epidermal growth factor receptor 2 her2positive metastatic breast cancer mbc nala phase 3 study methods nala nct01808573 patients randomized 11 neratinib capecitabine n c lapatinib capecitabine l c hrqol assessed using seven prespecified scores european organisation research treatment cancer quality life questionnaire core module qlqc30 breast cancerspecific questionnaire qlqbr23 baseline every 6 weeks descriptive statistics summarized scores time mixed models evaluated differences treatment arms kaplanmeier methods used assess time deterioration hrqol scores 10 points results 621 patients randomized nala patients included hrqol analysis completed baseline least one followup questionnaire summary global health status physical functioning fatigue constipation systemic therapy side effects scores stable time persistent differences treatment groups differences time deterioration ttd qlqc30 summary score treatment arms hazard ratio hr n c vs l c 094 95 ci 063140 diarrhea score worsened significantly n c arm compared l c arm remained time hr ttd n c vs l c 171 95 ci 132223 conclusion nala patients treated n c maintained global hrqol time despite worsening diarrhearelated scores results may help guide optimal treatment selection her2positive mbc
15,33902485,Predicting outcomes in older ED patients with influenza in real time using a big data-driven and machine learning approach to the hospital information system.,['2021/04/27 05:39'],background predicting outcomes older patients influenza emergency department ed machine learning ml never implemented therefore conducted study clarify clinical utility implementing ml methods recruited 5508 older ed patients 65 years old three hospitals 2009 2018 patients randomized 7030 split model training testing using 10 clinical variables electronic health records prediction model using synthetic minority oversampling technique preprocessing algorithm constructed predict five outcomes results best areas curves predicting outcomes random forest model hospitalization 0840 pneumonia 0765 sepsis septic shock 0857 xgboost intensive care unit admission 0902 logistic regression inhospital mortality 0889 testing data predictive model applied hospital information system assist physicians decisions real time conclusions ml promising way assist physicians predicting outcomes older ed patients influenza real time evaluations effectiveness impact needed future
16,33882374,Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients.,['2021/04/21 20:10'],background cancer patients considered highly vulnerable covid19 pandemic however delaying cancerspecific therapies could deleterious effect survival potential suppressive effects chemotherapies cancerrelated microenvironment raised question cancer patients immune system responds sarscov2 virus methods started prospective monocentric trial entitled covcrem nct04365322 april 2020 primary objective trial assess specific immune responses intensity diversity sarscov2 infected patients results study showed cancer patients 28 solid tumours 11 haematological malignancies exposed sarscov2 produced high rate specific antibodies observed patients without cancer history n 29 however results highlight lack generation tcell responses covn proteins sarscov2 virus suggesting cancer patients failed mount protective tcell immunity nevertheless sarscov2 infection impair established immune memory since specific responses common viruses hampered cancer patients conclusion given severity unknown evolution ongoing covid19 pandemic fundamental importance integrate cancer patients vaccination programs
17,33877728,"Effects of melatonin supplementation on serum oxidative stress markers and disease activity in systemic lupus erythematosus patients: A randomised, double-blind, placebo-controlled trial.",['2021/04/20 12:31'],background considering pathological significance oxidative stress systemic lupus erythematosus sle current research aimed evaluate effects melatonin supplementation oxidative stress markers disease activity sle method randomised doubleblind placebocontrolled trial 32 sle females selected randomly assigned two groups take 10 mgday melatonin placebo 12 weeks trial serum malondialdehyde mda total antioxidant capacity tac measured disease activity determined systemic lupus erythematosus disease activity index 2000 sledai2k results twentyfive patients 13 melatonin 12 placebo groups completed trial melatonin supplementation caused significant reduction serum mda compared baseline p 003 placebo group p 004 serum tac level change significantly melatonin group compared baseline placebo group p 05 furthermore melatonin supplementation cause significant change disease activity compared baseline placebo group p 05 conclusion study demonstrated affirmative effects melatonin decreasing oxidative stress sle patients without effect disease activity investigations required affirm primitive findings achieve concise conclusionswhats known free radical damage oxidative stress remarkable function systemic lupus erythematosus sle pathogenesis products derived oxidative modification cascades found biological fluids redundancy correlation disease activity organ damage sle dietary supplements decrease oxidative stress would useful managing sle melatonin potent antioxidant antiinflammatory immunomodulatory characteristics limited vitro animal studies available indicating desirable effects melatonin preventing sle organ damage thereby opening new area investigation contribute using melatonin therapy cotherapy sle whats new melatonin supplementation caused significant reduction serum mda compared baseline placebo group serum tac level change significantly melatonin group compared baseline placebo group furthermore melatonin supplementation cause significant change disease activity compared baseline placebo group
18,33877274,Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.,['2021/04/20 12:18'],importance although effective agents available prevent painful vasoocclusive episodes sickle cell disease scd diseasemodifying therapies ongoing painful vasoocclusive episodes treatment remains supportive previous phase 3 trial poloxamer 188 reported shortened duration painful vasoocclusive episodes scd particularly children participants treated hydroxyurea objective reassess efficacy poloxamer 188 vasoocclusive episodes design setting participants phase 3 randomized doubleblind placebocontrolled multicenter international trial conducted may 2013 february 2016 included 66 hospitals 12 countries 60 cities 388 individuals scd hemoglobin ss sc sbeta0 thalassemia sbeta thalassemia disease aged 4 65 years acute moderate severe pain typical painful vasoocclusive episodes requiring hospitalization included interventions 1hour 100mgkg loading dose poloxamer 188 intravenously followed 12hour 48hour 30mgkgh continuous infusion n 194 placebo n 194 main outcomes measures time hours randomization last dose parenteral opioids among participants among younger 16 years separate subgroup results 437 participants assessed eligibility 388 randomized mean age 152 years 176 454 female primary outcome available 384 990 15day followup contacts available 357 920 30day followup contacts available 368 948 significant difference groups mean time last dose parenteral opioids 818 h poloxamer 188 group vs 778 h placebo group difference 40 h 95 ci 78 157 geometric mean ratio 12 95 ci 1015 p 09 based significant interaction age treatment p 01 treatment difference time randomization last administration parenteral opioids participants younger 16 years 887 h poloxamer 188 group vs 719 h placebo group difference 168 h 95 ci 17320 geometric mean ratio 14 95 ci 1118 p 008 adverse events common poloxamer 188 group placebo group included hyperbilirubinemia 127 vs 52 common placebo group included hypoxia 120 vs 53 conclusions relevance among children adults scd poloxamer 188 significantly shorten time last dose parenteral opioids vasoocclusive episodes findings support use poloxamer 188 vasoocclusive episodes trial registration clinicaltrialsgov identifier nct01737814
19,33868301,Lung Neutrophilic Recruitment and IL-8/IL-17A Tissue Expression in COVID-19.,['2021/04/19 06:21'],new sarscov2 virus differs pandemic influenza virus h1n1 subtype h1n1pmd09 induces proinflammatory response infected patients study aims evaluate involvement snps tissue expression il17a neutrophils recruitment postmortem lung samples patients died severe forms covid19 comparing died h1n1pdm09 twenty lung samples patients sarscov2 infected covid19 group 10 lung samples adults died severe respiratory h1n1pdm09 infection h1n1 group tested tissue expression il8il17a identified immunohistochemistry hematoxylin eosin stain slides used neutrophil scoring dna extracted paraffin blocks genotyping done real timepcr two il17a target polymorphisms tissue expression increasing il8il17a higher number neutrophils identified samples h1n1 group compared covid19 group distribution genotype frequencies il17a gene statistically significant groups however g allele gg ga rs3819025 correlated higher tissue expression il17a covid19 group sarscov2 virus evokes exacerbated response hosts immune system differs observed h1n1pdm09 infection since il8il17a tissue expression lung neutrophilic recruitment may decreased snp rs3819025 ga g allele may considered risk allele patients died covid19
20,33861459,Protective Effects of Intravenous Magnesium Sulfate in Stroke Patients Receiving Amiodarone: A Randomized Controlled Trial.,['2021/04/16 12:20'],antiarrhythmic agents like amiodarone interfere different stages ischemic stroke however amiodarone accompanied immunological pulmonary complications adverse neurological effects hypothesize magnesium sulfate combination amiodarone holds promise stroke treatment thirtysix patients confirmed diagnosis ischemic stroke atrial fibrillation received bolus amiodarone randomly assigned magnesium sulfate every 24 h similar volume normal saline placebo 5 days various severity test scores used evaluate symptoms routing biochemistry also measured days 1 5 treatment mgso4 results significant reduction serum levels ngal hb tbill il6 il8 snse s100b egf paf crp igg also mgso4 treatment significantly improved rass candida sofa nihss apache scores moreover reduction il6 il8 snse egf apache score increase rass score significantly higher mgso4 group compared placebo intravenous administration mgso4 amiodaronetreated stroke patients improved inflammatory immunological neurological indicators reduced disability icuadmitted ais patients suggesting treatment scheme may prevent amiodaroneinduced complications patients
21,33861441,Effect of Curcumin on Severity of Functional Dyspepsia: a Triple Blinded Clinical Trial.,['2021/04/16 12:19'],backgroundfunctional dyspepsia main cause upper abdominal discomfort affecting 510 world population despite various therapeutic approaches 50 patients functional dyspepsia seek alternative treatments present study evaluated effect curcumin supplementation along famotidine therapy severity functional dyspepsia total 75 patients functional dyspepsia according rome iii criteria allocated intervention n 39 control n 36 groups intervention group treated combination 500 mg curcumin 40 mg famotidine daily 1 month control group received placebo 40 mg famotidine severity dyspepsia symptoms determined using hong kong questionnaire baseline 1 month treatment 1 month followup presence h pylori antigens stool samples also investigated subjects significant difference observed intervention control groups biochemical indices severity dyspepsia rate h pylori infection significant decrease observed severity dyspepsia p 0001 rate h pylori infection p 0004 immediately treatment followup curcumin intervention group study indicated curcumin therapy could favorable supplementation symptom management functional dyspepsia moreover curcumin could help efficient eradication h pylori patients
22,33861440,Therapeutic Effect of Curcumin in Women with Polycystic Ovary Syndrome Receiving Metformin: A Randomized Controlled Trial.,['2021/04/16 12:19'],polycystic ovary syndrome pcos common cause anovulatory infertility insulin sensitizer metformin used therapeutically shown curcumin also exhibits insulinsensitizing properties given metformin acts ovulation inducing agent curcumin metformin reduce insulin resistance aim current study evaluate effect metformin without curcumin nanomicelles treatment women polycystic ovary syndrome clinical trial conducted 100 women pcos diagnosed according rotterdam criteria sequentially recruited randomly divided two groups n 50 group 1 received 500 mg metformin three times daily group 2 received 80 mgday capsule curcumin nanomicelle 500 mg metformin three times day 3 months collecting fasting blood samples biochemical parameters including triglycerides highdensity lipoprotein cholesterol hdlc lowdensity lipoprotein cholesterol ldlc total cholesterol plasma glucose alanine amino transferase alt aspartate aminotransferase ast evaluated based enzymatic methods hormonal parameters assessed using immunoassay kits insulin resistance homair insulinsensitivity check index quicki also assessed treatment fasting insulin homair total testosterone group 2 significantly lower group 1 p 005 posttreatment ldlc levels groups 1 2 1179 24 9112 1946 mgdl respectively p 001 addition hdlc levels increased curcumin group 1 381 436 mgdl group 2 4412 73 mgdl p 005 total cholesterol decreased curcumin level group 1 2079 3984 mgdl group 2 1597 4843 mgdl p 005 decrease triglycerides levels group 1 1416 957 group 2 975 88 mgdl p 001 study showed curcumin synergistic effect metformin improvement insulin resistance lipid profile patients pcos therefore combined use metformin curcumin may therapeutic utility patients pcos
23,33861434,"The Effect of Curcumin Phytosome on the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.",['2021/04/16 12:19'],nonalcoholic fatty liver disease nafld global health problem increasing prevalence among overweight obese patients strongly associated conditions insulin resistance including type 2 diabetes mellitus t2dm obesity detrimental consequences ranged simple steatosis irreversible hepatic fibrosis cirrhosis curcumin dietary polyphenol potential effect improving nafld therefore aim trial examine effect curcumin supplementation various aspects nafld trial total number 80 patients randomised receive either curcumin 250 mg daily placebo 2 months lipid profiles hepatic enzymes anthropometric indices hepatic fat mass assessed baseline end trial compared within groups grade hepatic steatosis serum aspartate aminotransferase ast levels significantly reduced curcumin group p 0015 p 0007 respectively compared placebo also significant reduction high density lipoprotein hdl levels anthropometric indices groups significant differences two groups low dose phospholipid curcumin supplementation day 2 months showed significant reduction hepatic steatosis enzymes patients nafld compared placebo studies longer duration higher dosages needed assess effect parameters nafld including cardiovascular risk
24,33861432,"The Effect of Curcumin Supplementation on Pulse Wave Velocity in Patients with Metabolic Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.",['2021/04/16 12:19'],cardiovascular disease leading cause death many societies arterial stiffness initial sign structural functional changes arterial wall pulse wave velocity pwv gold standard noninvasive evaluation aortic stiffness modifiable cardiovascular risk factor curcumin major component turmeric known antiinflammatory antioxidative effects since arterial stiffness affected inflammation oxidative stress may improved curcumin supplementation purpose clinical trial investigate potential effects curcumin improving arterial stiffness patients metabolic syndrome placebocontrolled doubleblind randomized clinical trial conducted among metabolic syndrome patients sixtysix eligible individuals randomly assigned active intervention control groups active intervention group received curcumin supplement dose 500 mg daily 12 weeks whereas control group received placebo capsule physical activity daily dietary energy intake anthropometric body composition biochemical hemodynamic arterial stiffness parameters evaluated baseline end study body weight decreased significantly curcumin group compared placebo also curcumin intervention improved pwv remained significant adjustment potential confounding factors p 0011 current clinical trial demonstrated daily intake 500 mg curcumin 12 weeks lead improvement arterial stiffness weight management among subjects metabolic syndrome
25,33849723,"An open-label, comparative, single dose, clinical Phase study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults.",['2021/04/14 05:46'],injectable typhoid conjugate vaccine tcv provides longerlasting protection requires fewer doses suitable children aged 2 years addition tcv preferred ages owing improved immunological properties overcomes limitation vi polysaccharide vaccines assessed safety tolerability immunogenicity tcv vicrm197 termed eutcv openlabel clinical phase study healthy filipino adults study conducted 75 healthy adults aged 1845 years randomized 111 ratio based vaccines administered eutcv test typbartcvr prequalified vaccine typhim vir vi polysaccharide vaccine study vaccines administered dose 25 microg vicrm197 conjugate intramuscular injection single dose 25 participantsgroup immunogenicity overall safety assessed 42 days postvaccination study participants n 25group completed trial without dropouts deaths saes events leading premature withdrawal study antivi igg antibody titer geometric mean titer eutcv group day 42 65325 95 ci 36860 115771 significantly higher prequalified tcv 24795 95 ci 16164 38033 p 00055 vi polysaccharide vaccine 7998 95 ci 3800 16835 p 00001 moreover seroconversion rate eutcv typbartcvr 100 typhim vir 84 igg13 subclass titers serum bactericidal assay results eutcv group showed higher better bactericidal capacity groups eutcv well tolerated exhibited acceptable safety profile study population vicrm197 conjugate dose 25 mug may considered effective terms efficacy safety clinicaltrialsgov registration number nct03956524
